ArticleResearch and practice in thrombosis and haemostasis2025
High prevalence of factor XIII deficiency and its association with bleeding in extracorporeal membrane oxygenation patients: an observational study from a prospectively compiled biobank.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unlucky for some? Bleeding associated with factor XIII deficiency during extracorporeal membrane oxygenation.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coagulopathy is a major cause of death during extracorporeal membrane oxygenation (ECMO). Factor (F)XIII may play an important role in bleeding risk and represents a potential target for future therapies. Objectives: In order to explore the potential of using FXIII as a therapeutic target in ECMO, we assessed its activity, identified the risk factors associated with deficiency and evaluated its link to bleeding complications. Methods: This observational study investigated FXIII activity in adult ECMO patients using prospectively collected blood samples. The primary outcome was the prevalence of FXIII deficiency (<70%). Secondary outcomes included the incidence of bleeding complications according to the Bleeding Academic Research Consortium classification. Regression models were used to analyze risk factors for FXIII deficiency and its association with bleeding. Results: Between March 2020 and September 2023, FXIII activity was assessed in 101 ECMO patients undergoing a total of 108 ECMO runs. FXIII deficiency was identified in 73.3% ( Conclusion: In this cohort of adult ECMO patients, we observed a high prevalence of FXIII deficiency. FXIII deficiency was common in adult ECMO patients and associated with viral infections, venovenous ECMO, longer ECMO duration, and bleeding; its therapeutic potential warrants further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.